Oral Semaglutide 25 mg Outperforms Orforglipron 36 mg in Weight Loss and Tolerability for Obesity
Background
The global prevalence of obesity and overweight continues to rise, driving demand for effective and convenient weight management solutions. While injectable GLP-1 receptor agonists have shown significant efficacy, oral formulations offer improved patient adherence and accessibility. However, direct head-to-head comparisons between novel oral GLP-1R agonists like oral semaglutide and orforglipron are lacking, creating a gap in understanding their comparative effectiveness and tolerability in clinical practice. This study addresses this by providing an indirect comparison.
Study Design
Researchers conducted an anchored indirect treatment comparison (ITC) to evaluate oral semaglutide 25 mg versus orforglipron 36 mg. The analysis utilized individual patient data from the OASIS 4 trial (for oral semaglutide) and aggregate data from the ATTAIN-1 trial (for orforglipron). Baseline differences in sex, body weight, and normoglycemic status were adjusted using population-adjustment methods. Primary endpoints included percentage body weight change, categorical body weight loss thresholds, other cardiometabolic biomarkers, and tolerability outcomes such as treatment discontinuation due to any adverse event (AE) or gastrointestinal (GI) AEs.
Results
Population-adjusted analyses revealed a significantly greater percentage change from baseline in body weight with oral semaglutide 25 mg compared to orforglipron 36 mg. The mean difference (MD) was -3.2%-points (95% CIs: -5.9, -0.4) for the treatment-regimen estimand, and -3.0%-points (95% CI: -5.8, -0.3) for the efficacy estimand. This indicates superior weight loss with oral semaglutide. Tolerability also favored oral semaglutide, with significantly lower discontinuation rates for orforglipron. > Discontinuation due to any AE was higher with orforglipron (odds ratio [OR]: 4.1 [95% CI: 1.3, 13.0]), and discontinuation due to GI AEs was substantially higher (OR: 13.9 [95% CI: 2.0, 96.0]). These findings highlight a notable advantage in both efficacy and tolerability for oral semaglutide in this indirect comparison.
Key Findings
- Oral semaglutide 25 mg led to significantly greater body weight loss than orforglipron 36 mg.
- Mean difference in body weight change was -3.2%-points with oral semaglutide 25 mg.
- Discontinuation due to any adverse event was 4.1 times higher with orforglipron.
- Discontinuation due to gastrointestinal adverse events was 13.9 times higher with orforglipron.
Why It Matters
This indirect comparison provides crucial insights for clinicians and individuals managing obesity and overweight, offering a comparative view of two prominent oral GLP-1R agonists where head-to-head trials are unavailable. Oral semaglutide 25 mg appears to offer a more favorable balance of efficacy and tolerability, potentially leading to better patient outcomes and adherence. This information can guide treatment selection, suggesting that for patients prioritizing both significant weight loss and fewer gastrointestinal side effects, oral semaglutide might be the preferred option. The findings support its potential as a robust, convenient, and well-tolerated oral therapy in real-world clinical protocols.
semaglutide
orforglipron
obesity
overweight
weight-loss
glp-1-agonist